Please ensure Javascript is enabled for purposes of website accessibility
Coming soon · Rx only

The first and only FDA-authorized treatment for negative symptoms of schizophrenia.

Indication: Motivista is a prescription digital therapeutic indicated for the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms.

Clinical evidence

Backed by a rigorously designed pivotal study.

Motivista (CT-155) received FDA Breakthrough Device Designation and was then authorized on the basis of CONVOKE, a rigorously designed pivotal study. A pragmatic study, ENSPIRUS, is ongoing.

CONVOKE · Pivotal study

A double-blind, randomized controlled trial (RCT)

NCT05838625 · Participants randomized 1:1 to Motivista or digital control · Multi-site U.S. study · 457 patients · 16-week treatment period · Primary endpoint: CAINS-MAP at Week 16

LS mean CAINS-MAP change from baseline · Week 16

−6.8Motivista

(n=227)

−4.2Digital control

(n=230)

p=0.0003

Week 16 treatment difference −2.6 (95% CI −4.00, −1.20)

The CAINS (Clinical Assessment Interview for Negative Symptoms) is a semi-structured clinical interview used to assess negative symptoms of schizophrenia. Its motivation and pleasure subscale (CAINS-MAP) was the primary endpoint in CONVOKE.

Change in negative symptoms over 16 weeks

CONVOKE · CAINS-MAP LS mean change from baseline

CONVOKE primary endpoint: CAINS-MAP change from baseline Line chart of least-squares mean change in CAINS-MAP from baseline. Motivista improves from 0 at baseline to −5.3 at Week 8 and −6.8 at Week 16; digital control reaches −2.8 at Week 8 and −4.2 at Week 16. The Week 16 treatment difference is −2.6 points (p=0.0003). 0−2−4−6 LS mean change in CAINS-MAP Digital control, Baseline: 0 Digital control, Week 8: −2.8 Digital control, Week 16: −4.2 Motivista, Baseline: 0 Motivista, Week 8: −5.3 Motivista, Week 16: −6.8 −4.2 DIGITAL CONTROL −6.8 MOTIVISTA BaselineWeek 8Week 16

CAINS-MAP is a 9-item clinician-rated subscale of the CAINS (range 0–36); a reduction indicates improvement in negative symptoms. The primary effectiveness endpoint (change from baseline to Week 16 in CAINS-MAP total score) was analyzed using a prespecified Mixed Model Repeated Measures (MMRM) approach on the intent-to-treat (ITT) set with observed data, i.e., that included subjects with at least 1 post-baseline CAINS-MAP assessment (Week 8 and Week 16). The number of participants whose longitudinal data directly inform the primary MMRM is 196 (Motivista) and 204 (Digital control). Two prespecified sensitivity analyses were conducted using the full ITT set with imputation (N=457; 227 Motivista + 230 Digital control). Both sensitivity analyses, conducted on the complete N=457 ITT population, corroborated the primary result, supporting that the treatment effect estimated from the 196/204 MMRM analysis population is representative of the full ITT population.

CONVOKE CAINS-MAP least-squares mean change from baseline
GroupBaselineWeek 8Week 16
Motivista0−5.3−6.8
Digital control0−2.8−4.2

The Motivista clinical development program also includes an ongoing prospective pragmatic study, ENSPIRUS (NCT06791122), evaluating Motivista's effectiveness, engagement, and safety in routine clinical practice. Early phase research includes published exploratory studies establishing early feasibility (an exploratory 7-week feasibility study) and formation of the Digital Working Alliance (JMIR Mental Health, 2025).

About Motivista

A 16-week prescription digital therapeutic, delivered in the hand of patients directly.

Prescription only

Motivista is a software-based treatment for the negative symptoms of schizophrenia, prescribed as an adjunct to clinician-managed antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms. It delivers evidence-based psychosocial techniques directly into the patient's daily environment, without adding extra clinic visits.

Patients engage with Motivista in brief, daily sessions, working toward meaningful goals across three areas: recreation, social connection, and productivity.

How it works

Motivista combines key elements of evidence-based psychosocial therapies with unique digital methods.

Motivista helps patients rebuild motivation and re-engage with life, using a fully digital approach to treat negative symptoms of schizophrenia.

Adaptive Goal Setting

Aims to counter avolition by breaking activities into achievable, personalized goals designed to rebuild motivation and agency.

Behavioral Activation

Targets avolition and anhedonia by re-engaging patients in goal-directed, rewarding activity despite low anticipated motivation or pleasure.

Cognitive Restructuring

Targets defeatist performance beliefs associated with negative symptoms by helping patients identify these thoughts and reframe them into more accurate and helpful alternatives.

Positive Affect Training

Targets anhedonia by helping patients notice, anticipate, and savor positive experiences.

Social Skills Training

Addresses asociality by building confidence and competence for social interaction, which may support more rewarding relationships.

Distress Tolerance

Aims to reduce avoidance by building skills to manage difficult emotions, supporting engagement in goal-directed activity.

Motivista may help

  • Improve motivation
  • Support social engagement
  • Restore joy in activities

Coming Soon

Motivista will be available by prescription only. Click Therapeutics is working to ensure Motivista reaches people through a careful, deliberate distribution process. We're also in active discussions with payers across the country to make it accessible to patients.

Stay in touch

Be the first to know when Motivista is available.

We'll share updates here and by email as each stage moves forward.

See our Privacy Policy for how we handle your information.

Back to top